Table 2.
The mean absorbed dose per administered activity
|
Patient number |
First treatment cycle |
D/Aadministered(Gy/GBq) |
||||
|---|---|---|---|---|---|---|
| |
Kidney size/mass/AP thickness (cm/kg/cm) |
|
|
Treatment cycle |
|
|
| 1 | 2 | 3 | 4 | 5 | ||
| 1 |
Right (5.5/0.129/27) |
0.68 |
0.87 |
0.72 |
0.51 |
ND |
| Left |
NA |
NA |
NA |
NA |
ND |
|
| 2 |
Right (6.8/0.168/17) |
0.38 |
0.48 |
0.45 |
0.37 |
0.52 |
| Left (5.7/0.194/17) |
0.43 |
0.70 |
0.57 |
0.52 |
0.33 |
|
| 3 |
Right (6.6/0.190/19) |
1.09 |
0.76 |
0.82 |
0.84 |
ND |
| Left (5.27/0.154/19) |
0.91 |
0.68 |
0.76 |
0.86 |
ND |
|
| 4 |
Right |
NA |
NA |
NA |
NA |
ND |
| Left (4.3/0.113/21) |
0.86 |
0.77 |
0.84 |
0.95 |
ND |
|
| 5 |
Right |
NP |
NP |
NP |
NP |
NP |
| Left (6.4/0.234/23) |
0.74 |
0.57 |
0.76 |
ND |
ND |
|
| 6 |
Right (5.4/0.135/23) |
0.89 |
ND |
ND |
ND |
ND |
| Left (5.6/0.137/22) |
0.56 |
ND |
ND |
ND |
ND |
|
| 7 |
Right (6.6/0.190/24) |
0.60 |
0.60 |
0.62 |
ND |
ND |
| Left (5.8/0.161/25) |
0.78 |
0.79 |
0.69 |
ND |
ND |
|
| 8 |
Right (5.5/0.123/22) |
0.60 |
0.60 |
0.62 |
1.1 |
ND |
| Left (5.0/0.152/23) |
0.78 |
0.79 |
0.69 |
0.74 |
ND |
|
| 9 |
Right (5.4/0.135/16) |
0.96 |
1.2 |
ND |
ND |
ND |
| Left (3.0/0.054/18) |
1.7 |
2.4 |
ND |
ND |
ND |
|
| 10 |
Right (5.9/0.138/18) |
1.2 |
1.3 |
ND |
ND |
ND |
| Left (5.6/0.149/17) |
0.91 |
1.2 |
ND |
ND |
ND |
|
| 11 |
Right (5.4/0.157/20) |
0.77 |
0.94 |
0.92 |
1.1 |
ND |
| Left (6.3/0.177/20) |
0.69 |
0.73 |
0.94 |
0.87 |
ND |
|
| 12 |
Right (6.3/0.137/16) |
0.73 |
0.61 |
0.59 |
ND |
ND |
| Left (5.8/0.168/17) |
0.74 |
0.68 |
0.78 |
ND |
ND |
|
| 13 |
Right (5.1/0.131/19) |
0.59 |
0.87 |
0.79 |
ND |
ND |
| Left (5.1/0.107/20) |
NA |
NA |
NA |
ND |
ND |
|
| 14 |
Right (3.7/0.087/18) |
NA |
NA |
NA |
ND |
ND |
| Left (4.7/0.088/19) |
0.94 |
1.0 |
0.97 |
ND |
ND |
|
| 15 |
Right (5.7/0.159/19) |
1.3 |
ND |
ND |
ND |
ND |
| Left (5.2/0.188/18) |
1.3 |
ND |
ND |
ND |
ND |
|
| 16 |
Right (6.5/0.215/25) |
0.63 |
0.59 |
0.61 |
0.56 |
ND |
| Left (6.3/0.231/26) |
0.52 |
0.52 |
0.47 |
0.51 |
ND |
|
| 17 |
Right (5.6/0.187/23) |
0.50 |
0.47 |
0.50 |
0.63 |
ND |
| Left (6.4/0.215/24) |
0.49 |
0.52 |
0.50 |
0.52 |
ND |
|
| 18 |
Right (5.3/0.132/17) |
0.85 |
0.88 |
0.94 |
ND |
ND |
| Left (5.2/0.117/19) |
1.0 |
1.1 |
1.0 |
ND |
ND |
|
| 19 |
Right |
NA |
NA |
NA |
ND |
ND |
| Left (4.5/0.094/21) |
1.2 |
0.97 |
1.3 |
ND |
ND |
|
| 20 |
Right (5.6/0.184/23) |
0.66 |
0.56 |
0.57 |
0.57 |
ND |
| Left (5.6/0.153/23) |
0.77 |
0.67 |
0.68 |
0.61 |
ND |
|
| 21 |
Right (5.9/0.091/16) |
1.5 |
1.6 |
ND |
ND |
ND |
| Left (4.7/0.098/18) |
1.3 |
1.3 |
ND |
ND |
ND |
|
| 22 |
Right (5.6/0.162/23) |
0.73 |
0.74 |
0.73 |
0.64 |
ND |
| Left (5.6/0.194/24) |
0.74 |
0.72 |
0.66 |
0.60 |
ND |
|
| 23 |
Right |
NA |
NA |
NA |
ND |
ND |
| Left (4.7/0.124/20) |
0.70 |
0.83 |
0.84 |
ND |
ND |
|
| 24 |
Right |
NA |
NA |
NA |
NA |
ND |
| Left (5.6/0.167/24) |
0.86 |
0.74 |
0.80 |
0.73 |
ND |
|
| 25 |
Right (5.9/0.186/24) |
0.55 |
0.48 |
0.44 |
0.46 |
ND |
| Left (5.9/0.209/26) |
0.52 |
0.47 |
0.40 |
0.46 |
ND |
|
| 26 |
Right (7.0/0.189/32) |
1.3 |
1.4 |
ND |
ND |
ND |
| Left (5.5/0.145/30) |
1.5 |
1.3 |
ND |
ND |
ND |
|
| 27 |
Right (5.6/0.156/23) |
1.2 |
1.3 |
1.2 |
ND |
ND |
| Left (6.1/0.200/22) |
0.68 |
1.2 |
1.3 |
ND |
ND |
|
| 28 |
Right (4.4/0.111/18) |
1.0 |
1.0 |
ND |
ND |
ND |
| Left (5.1/0.158/19) |
1.1 |
1.0 |
ND |
ND |
ND |
|
| 29 |
Right |
NA |
NA |
NA |
NA |
ND |
| Left (5.6/0.181/21) |
0.59 |
0.67 |
0.65 |
0.81 |
ND |
|
| 30 |
Right (6.1/0.192/21) |
0.51 |
0.48 |
0.43 |
ND |
ND |
| Left |
NA |
NA |
NA |
ND |
ND |
|
| 31 |
Right |
NA |
NA |
ND |
ND |
ND |
| Left (4.9/0.118/18) |
0.58 |
0.49 |
ND |
ND |
ND |
|
| 32 |
Right (6.2/0.155/24) |
0.95 |
NA |
ND |
ND |
ND |
| Left (6.4/0.168/24) |
0.72 |
0.75 |
ND |
ND |
ND |
|
| 33 | Right (5.3/0.116/23) |
1.0 |
ND |
ND |
ND |
ND |
| Left (5.3/0.161/22) | 0.65 | ND | ND | ND | ND | |
NP, not present; NA, not analyzable; ND, not done. The mean absorbed dose per administered activity (Gy/GBq) to the right and left kidneys for each patient given for each treatment cycle (1 to 5 per patient). Patient no. 5 had only one kidney. For patients no. 1, 4, 13, 14, 19, 23, 24, 29, 30, 31, and 32, it was not possible to determine the absorbed dose to one of the kidneys for one or several treatment cycles (see text).